Paul Tudor Jones’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-10,381
| Closed | -$131K | – | 3752 |
|
|
2026
Q1 | $131K | Buy |
+10,381
| New | +$139K | ﹤0.01% | 3439 |
|
|
2025
Q4 | – | Sell |
-10,443
| Closed | -$125K | – | 3628 |
|
|
2025
Q3 | $125K | Buy |
+10,443
| New | +$83.5K | ﹤0.01% | 3249 |
|
|
2025
Q2 | – | Sell |
-10,347
| Closed | -$57.1K | – | 3380 |
|
|
2025
Q1 | $57.1K | Hold |
10,347
| – | – | ﹤0.01% | 2954 |
|
|
2024
Q4 | $59.5K | Sell |
10,347
-2
| -0% | -$19 | ﹤0.01% | 2925 |
|
|
2024
Q3 | $107K | Buy |
+10,349
| New | +$135K | ﹤0.01% | 2590 |
|
|
2024
Q2 | – | Sell |
-10,405
| Closed | -$182K | – | 2440 |
|
|
2024
Q1 | $182K | Buy |
+10,405
| New | +$138K | ﹤0.01% | 2054 |
|
|
2023
Q3 | – | Sell |
-10,365
| Closed | -$222K | – | 2433 |
|
|
2023
Q2 | $222K | Buy |
+10,365
| New | +$306K | ﹤0.01% | 2169 |
|
|
2022
Q4 | – | Sell |
-10,327
| Closed | -$536K | – | 2508 |
|
|
2022
Q3 | $536K | Sell |
10,327
-1,659
| -14% | -$96.9K | 0.01% | 1344 |
|
|
2022
Q2 | $567K | Sell |
11,986
-17,268
| -59% | -$937K | 0.01% | 1213 |
|
|
2022
Q1 | $2.08M | Buy |
29,254
+2,308
| +9% | +$150K | 0.05% | 534 |
|
|
2021
Q4 | $2.02M | Buy |
26,946
+19,049
| +241% | +$1.49M | 0.03% | 619 |
|
|
2021
Q3 | $449K | Sell |
7,897
-43,479
| -85% | -$2.15M | 0.01% | 1731 |
|
|
2021
Q2 | $2.26M | Buy |
51,376
+31,365
| +157% | +$1.54M | 0.04% | 512 |
|
|
2021
Q1 | $987K | Sell |
20,011
-24,075
| -55% | -$1.2M | 0.02% | 841 |
|
|
2020
Q4 | $1.86M | Buy |
+44,086
| New | +$1.94M | 0.05% | 446 |
|
|
2020
Q3 | – | Sell |
-11,227
| Closed | -$564K | – | 1357 |
|
|
2020
Q2 | $564K | Buy |
+11,227
| New | +$581K | 0.03% | 679 |
|
|
2017
Q3 | – | Sell |
-5,802
| Closed | -$209K | – | 1127 |
|
|
2017
Q2 | $209K | Sell |
5,802
-6,100
| -51% | -$195K | 0.01% | 873 |
|
|
2017
Q1 | $367K | Sell |
11,902
-3,568
| -23% | -$111K | 0.01% | 874 |
|
|
2016
Q4 | $518K | Buy |
+15,470
| New | +$443K | 0.01% | 703 |
|
|
2015
Q2 | – | Sell |
-9,800
| Closed | -$300K | – | 1533 |
|
|
2015
Q1 | $300K | Buy |
9,800
+813
| +9% | +$31.6K | 0.01% | 1049 |
|
|
2014
Q4 | $457K | Sell |
8,987
-11,609
| -56% | -$520K | 0.02% | 788 |
|
|
2014
Q3 | $815K | Buy |
+20,596
| New | +$821K | 0.03% | 385 |
|
Other funds holding ENTA
JT
KAM
FCM
DTC
ACM
SSC
Paul Tudor Jones's ENTA Position: Q2 2026 in Review
Paul Tudor Jones sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 10,381 shares — an estimated $131K sold.
Paul Tudor Jones first reported a position in ENTA in Q3 2014 and held it in 22 quarters. The position peaked at $2.26M in Q2 2021. 121 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Paul Tudor Jones reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Paul Tudor Jones sold 10,381 Enanta Pharmaceuticals shares in Q2 2026, an estimated $131K.
- Paul Tudor Jones first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 22 quarters.
- Paul Tudor Jones's Enanta Pharmaceuticals position peaked at $2.26M in Q2 2021.
- 121 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.